PTEN loss of function is linked to various sporadic human cancers, including endometrial, glioblastoma, melanoma, lung, breast and prostate, with an average mutational frequency rate of ∼25% (refs 15, 33, 34). This evidence concerns the gene PTEN and glioblastoma.